YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
Background: YAP1, an oncogene in numerous cancers, is a downstream transcription factor of the Hippo pathway. This study focuses on its relationship with the Oncotype Dx (ODX) test risk score (RS) in patients with hormone-receptor-positive, HER2-negative (HR+HER2−) breast cancer. Methods: We retrosp...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/20/5034 |
| _version_ | 1797574343133233152 |
|---|---|
| author | Inho Park Yangkyu Lee Jee Hung Kim Soong June Bae Sung Gwe Ahn Joon Jeong Yoon Jin Cha |
| author_facet | Inho Park Yangkyu Lee Jee Hung Kim Soong June Bae Sung Gwe Ahn Joon Jeong Yoon Jin Cha |
| author_sort | Inho Park |
| collection | DOAJ |
| description | Background: YAP1, an oncogene in numerous cancers, is a downstream transcription factor of the Hippo pathway. This study focuses on its relationship with the Oncotype Dx (ODX) test risk score (RS) in patients with hormone-receptor-positive, HER2-negative (HR+HER2−) breast cancer. Methods: We retrospectively analyzed 401 HR+HER2− breast cancer patients from Gangnam Severance Hospital who underwent ODX tests (May 2014–April 2020). YAP1 nuclear localization was evaluated via immunohistochemical staining and its clinical correlation with clinicopathological parameters, including RS, was analyzed. Public datasets TCGA-BRCA and METABRIC validated clinical outcomes. Results: YAP1 expression negatively correlated with ODX RS (OR 0.373, <i>p</i> = 0.002). Elevated YAP1 mRNA levels corresponded to better clinical outcomes, specifically in ER-positive patients, with significant results in METABRIC and TCGA-BRCA datasets (<i>p</i> < 0.0001 OS in METABRIC, <i>p</i> = 0.00085 RFS in METABRIC, <i>p</i> = 0.040 DFS in TCGA-BRCA). In subsets with varying ESR1 mRNA expression and pronounced YAP1 expression, superior survival outcomes were consistently observed. Conclusion: YAP1 may be a valuable prognostic marker and potential therapeutic target in HR+HER2− breast cancer patients. |
| first_indexed | 2024-03-10T21:21:39Z |
| format | Article |
| id | doaj.art-71b7e6e24df04dcfaa328f3cdee825c7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T21:21:39Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-71b7e6e24df04dcfaa328f3cdee825c72023-11-19T15:59:38ZengMDPI AGCancers2072-66942023-10-011520503410.3390/cancers15205034YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset ValidationInho Park0Yangkyu Lee1Jee Hung Kim2Soong June Bae3Sung Gwe Ahn4Joon Jeong5Yoon Jin Cha6Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of KoreaDepartment of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of KoreaInstitute of Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul 06273, Republic of KoreaInstitute of Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul 06273, Republic of KoreaInstitute of Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul 06273, Republic of KoreaInstitute of Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul 06273, Republic of KoreaDepartment of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of KoreaBackground: YAP1, an oncogene in numerous cancers, is a downstream transcription factor of the Hippo pathway. This study focuses on its relationship with the Oncotype Dx (ODX) test risk score (RS) in patients with hormone-receptor-positive, HER2-negative (HR+HER2−) breast cancer. Methods: We retrospectively analyzed 401 HR+HER2− breast cancer patients from Gangnam Severance Hospital who underwent ODX tests (May 2014–April 2020). YAP1 nuclear localization was evaluated via immunohistochemical staining and its clinical correlation with clinicopathological parameters, including RS, was analyzed. Public datasets TCGA-BRCA and METABRIC validated clinical outcomes. Results: YAP1 expression negatively correlated with ODX RS (OR 0.373, <i>p</i> = 0.002). Elevated YAP1 mRNA levels corresponded to better clinical outcomes, specifically in ER-positive patients, with significant results in METABRIC and TCGA-BRCA datasets (<i>p</i> < 0.0001 OS in METABRIC, <i>p</i> = 0.00085 RFS in METABRIC, <i>p</i> = 0.040 DFS in TCGA-BRCA). In subsets with varying ESR1 mRNA expression and pronounced YAP1 expression, superior survival outcomes were consistently observed. Conclusion: YAP1 may be a valuable prognostic marker and potential therapeutic target in HR+HER2− breast cancer patients.https://www.mdpi.com/2072-6694/15/20/5034breast neoplasmsYes-associated protein 1prognosisreceptorsestrogenpathology |
| spellingShingle | Inho Park Yangkyu Lee Jee Hung Kim Soong June Bae Sung Gwe Ahn Joon Jeong Yoon Jin Cha YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation Cancers breast neoplasms Yes-associated protein 1 prognosis receptors estrogen pathology |
| title | YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation |
| title_full | YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation |
| title_fullStr | YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation |
| title_full_unstemmed | YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation |
| title_short | YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation |
| title_sort | yap1 expression in hr her2 breast cancer 21 gene recurrence score analysis and public dataset validation |
| topic | breast neoplasms Yes-associated protein 1 prognosis receptors estrogen pathology |
| url | https://www.mdpi.com/2072-6694/15/20/5034 |
| work_keys_str_mv | AT inhopark yap1expressioninhrher2breastcancer21generecurrencescoreanalysisandpublicdatasetvalidation AT yangkyulee yap1expressioninhrher2breastcancer21generecurrencescoreanalysisandpublicdatasetvalidation AT jeehungkim yap1expressioninhrher2breastcancer21generecurrencescoreanalysisandpublicdatasetvalidation AT soongjunebae yap1expressioninhrher2breastcancer21generecurrencescoreanalysisandpublicdatasetvalidation AT sunggweahn yap1expressioninhrher2breastcancer21generecurrencescoreanalysisandpublicdatasetvalidation AT joonjeong yap1expressioninhrher2breastcancer21generecurrencescoreanalysisandpublicdatasetvalidation AT yoonjincha yap1expressioninhrher2breastcancer21generecurrencescoreanalysisandpublicdatasetvalidation |